What is it?
What Nefiracetam is
1Nefiracetam is a synthetic racetam compound also known as DM-9384. PubChem records the chemical identity; an identity record does not establish a consumer cognitive benefit or safety profile.
Names, aliases and forms
Mechanisms of action
Mechanistic receptor work is not an outcome
5The reviewed mechanism literature discusses neuronal receptor modulation, including work in rat cortical neurons. This does not demonstrate a healthy-human cognition effect.
Potential effects and evidence map
The reviewed Nefiracetam evidence combines healthy-volunteer pharmacokinetics, small patient-context trials, mechanistic animal-neuron work, and repeated-dose dog toxicology. The patient evidence is inconsistent and population-specific, while the mechanistic work is not a healthy-user outcome. This does not establish a consumer cognitive benefit, self-use amount, product form, combination, or long-term safety margin.
Typical dosages and timing
The healthy-volunteer pharmacokinetic study used controlled research amounts. Those methods are not a consumer dose, route, timing, or repeat-use protocol.
Timing & effect horizon
In one healthy-volunteer pharmacokinetic study, peak concentration was reported within two hours. This is a study observation, not a consumer onset promise.
Safety, side effects and risk profile
In a 52-week dog study, kidney and testis were identified as high-exposure toxicity targets. Human relevance and a consumer safety threshold are not established.
Repeated-dose dog research reported reproductive findings including lower testosterone and altered semen parameters at high exposure. Human relevance and thresholds are not established.
Human evidence is limited and population-specific, and it does not provide a consumer product or long-term safety framework.
The reviewed source set did not identify a robust human interaction study; this is an evidence gap, not a demonstrated interaction hazard.
The reviewed sources do not provide a pregnancy or lactation safety framework; this is an evidence gap, not a demonstrated outcome.
A 52-week dog study identified kidney and testis findings at high exposure. It does not establish a human safety threshold, but it is not a reason to infer safety for self-use.
A dog reproductive toxicology study reported testosterone, semen, and testicular changes at high exposure. Human relevance and thresholds remain unknown.
Interactions and cautions
The reviewed sources did not identify a robust human interaction study that establishes a safe combination profile. This page makes no mixing recommendation.
Practical buying and quality notes
- No active product offer is currently mapped to this profile. This page provides evidence context only and does not validate a current product, price, or source.1
- Published research context does not create a consumer dose, safety margin, or monitoring plan. The profile does not turn study methods into self-use guidance.2
FAQ
What is Nefiracetam?
1Nefiracetam is a synthetic racetam compound also called DM-9384. It has identity and pharmacology research, but that does not establish a healthy-user nootropic benefit.
What did the PK study report?
2A healthy-volunteer pharmacokinetic study reported peak concentration within two hours and a three-to-five-hour half-life. These observations are not dose or schedule guidance.
Does Nefiracetam improve memory or focus?
4No reliable healthy-user memory or focus benefit was established. Mechanistic research and small patient-context studies should not become productivity claims.
Why are animal safety findings included?
6Repeated-dose dog studies reported renal and reproductive signals at high exposure. They do not quantify human risk, but they limit claims of consumer safety.
Is a consumer Nefiracetam dose established?
2No. The reviewed evidence does not establish a consumer dose, route, cycle, or long-term safety margin.
References
- PubChem. Nefiracetam (CID 71157). Accessed 2026-08-21.
- Fujimaki Y, et al. Single- and multiple-dose pharmacokinetics of nefiracetam, a new nootropic agent, in healthy volunteers. J Pharm Pharmacol. 1992;44(9):750-754.
- Robinson RG, et al. Double-blind treatment of apathy in patients with poststroke depression using nefiracetam. J Neuropsychiatry Clin Neurosci. 2009;21(2):144-151.
- Starkstein SE, et al. A randomized, placebo-controlled, double-blind efficacy study of nefiracetam to treat poststroke apathy. J Stroke Cerebrovasc Dis. 2016;25(5):1119-1127.
- Zhao X, Yeh JZ, Narahashi T. Post-stroke dementia. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors. Ann N Y Acad Sci. 2001;939:179-186.
- Hooks WN, et al. Fifty-two-week oral toxicity study of the new cognition-enhancing agent nefiracetam in dogs. Arzneimittelforschung. 1994;44(2A):228-238.
- Shimomura K, et al. Testicular toxicity induced in dogs by nefiracetam, a neutrotransmission enhancer. Reprod Toxicol. 2004;18(3):423-430.
- NootropicsIndex indexed listing. Nefiracetam powder, 10 g. Accessed 2026-07-01.